NHS Clinical Commissioners co-ordinate support from CCGs to review use of Avastin to treat wet AMD
College Statement In response to the public letters sent by the NHS Clinical Commissioners to Secretary of State for Health, cc. Chair of NICE; Simon Stevens at NHS England; and the Chair of the GMC and signed by the Clinical Chair / Lead Clinician of 120 CCGs regarding the use of Avastin to treat wet AMD. The Royal
Cataract Provision – RCOphth statement
The Royal College of Ophthalmologists (RCOphth) sets the standards for all eye healthcare, including eye surgery, and it is very concerned about the reports from Musgrove Park Hospital. Cataract surgery is a highly effective, life-enhancing procedure which, if performed according to RCOphth standards in a safe environment, carries very little risk. We recommend that surgical
Use of Avastin (bevacizumab) in age related macular degeneration
Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no
RCOphth calls for review of Avastin for use in AMD treatment
Professor Carrie MacEwen and Professor Andrew Lotery co-author the editorial ‘What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?’, published online on BMJ, calls for UK regulatory bodies to review and appraise use of bevacizumab for use in AMD treatment. Ranibizumab (Lucentis), the first drug used to treat this
Survey finds nearly 70% of patients waiting too long for treatment
A survey of ophthalmologists found that nearly 70% of patients with wet age-related macular degeneration (AMD) had to wait more than the recommended two weeks for their first sight-saving injection. Many also wait too long for follow up treatment. The Royal College of Ophthalmologists and the Macular Society say their research shows that more resources